Mansi Shah, MD, explains how treatment sequencing and patient eligibility guide the use of these therapies in multiple ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or ...

I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened ...

The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug ...

Researchers sought to determine whether CAR-T therapy could improve HR-QoL scores for patients with relapsed or refractory multiple myeloma.

A single infusion of cilta-cel CAR-T therapy led to five-year remission without maintenance therapy in 33% of patients with heavily pretreated relapsed or refractory multiple myeloma.

Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...

A Harrisburg grandfather bikes thousands of miles a yearfighting against his multiple myeloma cancer. CBS 21’s Alex Thill sat ...

An immunotherapy for multiple myeloma, a form of blood cancer, is showing promising treatment results in a new study. Dr.

Arcellx , Inc. (NASDAQ: ACLX), a biotechnology company at the forefront of developing innovative treatments for multiple myeloma, has been garnering significant attention from investors and analysts ...

GILBERT, AZ (AZFamily) — A potential cure for a rare type of blood cancer is currently being used to treat 150 patients at various healthcare centers in the Valley. Details about the medical ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.